Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center
Objective: Medication-related osteonecrosis of the jaw (MRONJ), a complication of bisphosphonate therapy, has significant morbidity. This study aimed to determine the prevalence of MRONJ and compare its risks among patients who received antiresorptive or antiangiogenic therapy in King Fahad Medical...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-09-01
|
| Series: | Saudi Dental Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S101390522200075X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850259012214325248 |
|---|---|
| author | Saad Hajeri, BDS Yasir Alturkistany, BDS, MBA |
| author_facet | Saad Hajeri, BDS Yasir Alturkistany, BDS, MBA |
| author_sort | Saad Hajeri, BDS |
| collection | DOAJ |
| description | Objective: Medication-related osteonecrosis of the jaw (MRONJ), a complication of bisphosphonate therapy, has significant morbidity. This study aimed to determine the prevalence of MRONJ and compare its risks among patients who received antiresorptive or antiangiogenic therapy in King Fahad Medical City. Study design: In this retrospective study, the sample comprised data of all patients referred for dental treatment before antiresorptive and antiangiogenic therapy between 2008 and 2018. All patients were classified as at risk or having stage 0, stage 1, stage 2, or stage 3 MRONJ. Results: The sample comprised 622 patients, including 358 (249 IV route, 34 oral route, and 75 subcutaneous route) who fulfilled the inclusion criteria and 25 in stage ≥ 0. Greater risk was observed in the intravenous group (8.82%) than in the oral and subcutaneous groups (2.94% and 2.67%, respectively). The overall prevalence rate was 6%. Patients with no history of dentoalveolar surgery had an MRONJ rate of 1.03%, whereas patients who underwent dentoalveolar surgery > 3 weeks before a lower MRONJ rate of 0.96%. Patients who underwent dentoalveolar surgery < 3 weeks before starting medication, and those who underwent surgery after starting the medication had higher MRONJ rates (21.42%, and 35.85%, respectively). The risk of spontaneously developing MRONJ was low. Conclusion: Risk of developing MRONJ was found to be higher when dentoalveolar procedures performed within 3 week before starting antiresorptive medications. |
| format | Article |
| id | doaj-art-a92d5c6936d64c129380809cb8195df8 |
| institution | OA Journals |
| issn | 1013-9052 |
| language | English |
| publishDate | 2022-09-01 |
| publisher | Springer |
| record_format | Article |
| series | Saudi Dental Journal |
| spelling | doaj-art-a92d5c6936d64c129380809cb8195df82025-08-20T01:55:58ZengSpringerSaudi Dental Journal1013-90522022-09-0134647948410.1016/j.sdentj.2022.06.004Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology centerSaad Hajeri, BDS0Yasir Alturkistany, BDS, MBA1Corresponding author at: Oral and Maxillofacial Surgery, King Fahad Medical City, P.O. Box. 59046, Riyadh 11525, Saudi Arabia.; Oral & Maxillofacial Surgery, Maxillofacial Surgery and Rehabilitation Department, King Fahad Medical City, Riyadh, Saudi ArabiaOral & Maxillofacial Surgery, Maxillofacial Surgery and Rehabilitation Department, King Fahad Medical City, Riyadh, Saudi ArabiaObjective: Medication-related osteonecrosis of the jaw (MRONJ), a complication of bisphosphonate therapy, has significant morbidity. This study aimed to determine the prevalence of MRONJ and compare its risks among patients who received antiresorptive or antiangiogenic therapy in King Fahad Medical City. Study design: In this retrospective study, the sample comprised data of all patients referred for dental treatment before antiresorptive and antiangiogenic therapy between 2008 and 2018. All patients were classified as at risk or having stage 0, stage 1, stage 2, or stage 3 MRONJ. Results: The sample comprised 622 patients, including 358 (249 IV route, 34 oral route, and 75 subcutaneous route) who fulfilled the inclusion criteria and 25 in stage ≥ 0. Greater risk was observed in the intravenous group (8.82%) than in the oral and subcutaneous groups (2.94% and 2.67%, respectively). The overall prevalence rate was 6%. Patients with no history of dentoalveolar surgery had an MRONJ rate of 1.03%, whereas patients who underwent dentoalveolar surgery > 3 weeks before a lower MRONJ rate of 0.96%. Patients who underwent dentoalveolar surgery < 3 weeks before starting medication, and those who underwent surgery after starting the medication had higher MRONJ rates (21.42%, and 35.85%, respectively). The risk of spontaneously developing MRONJ was low. Conclusion: Risk of developing MRONJ was found to be higher when dentoalveolar procedures performed within 3 week before starting antiresorptive medications.http://www.sciencedirect.com/science/article/pii/S101390522200075XMRONJosteonecrosis of the jawalendronateoral bisphosphonatesdenosumab |
| spellingShingle | Saad Hajeri, BDS Yasir Alturkistany, BDS, MBA Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center Saudi Dental Journal MRONJ osteonecrosis of the jaw alendronate oral bisphosphonates denosumab |
| title | Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center |
| title_full | Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center |
| title_fullStr | Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center |
| title_full_unstemmed | Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center |
| title_short | Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center |
| title_sort | medication related osteonecrosis of the jaw after dental clearance prevalence in an oncology center |
| topic | MRONJ osteonecrosis of the jaw alendronate oral bisphosphonates denosumab |
| url | http://www.sciencedirect.com/science/article/pii/S101390522200075X |
| work_keys_str_mv | AT saadhajeribds medicationrelatedosteonecrosisofthejawafterdentalclearanceprevalenceinanoncologycenter AT yasiralturkistanybdsmba medicationrelatedosteonecrosisofthejawafterdentalclearanceprevalenceinanoncologycenter |